Happy DNA Day! To celebrate, we’ve put together a timeline of some of the major events that have happened in genomics since 1953 – See how far we’ve come!
The advancement of sequencing technology has had the singe biggest effect on genomics research. As it develops further, so does the scope of genomic research and applications.
AI genomics company Freenome has announced a partnership with proteomics company Biognosys, to enhance its broad-signal approach to early-cancer detection and precision oncology.
Illumina’s new Bay Area campus boasts connectivity, collaboration, and innovation, but some are unsure whether it will be able to draw in the appeal from workers.
The gene atlas enables a new functional view on how we study the human genome, and provides a tool that will change how we study and treat cancer and genetic disorders.
Scientists have identified a new culprit that may explain what causes the remaining risk of autism: rare inherited variants in regions of non-coding DNA.
Thermo Fisher Scientific has launched the Oncomine Childhood Cancer Research Assay, a next-generation sequencing panel developed in collaboration with Children’s Hospital Los Angeles.
A team of scientists at GRAIL has announced progression towards the goal of a simple blood test being able to detect a small tumour growing in your body.
To fully benefit from the vast quantities of data from TCGA, tools for easy data visualisation and analysis must be developed for use of the non-computational scientist. Our panel of experts discuss TCGA data and the tools needed to make sense of it.
Researchers around the globe can now access thousands of paediatric cancer genomic datasets, thanks to a new cloud-based initiative.
The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB).
The FDA said yesterday it will relax its review of some genetic tests that examine millions of different variants at the same time, and finalised two guidances designed to enhance collaboration among researchers, and drive the efficient development of novel NGS-based tests.
Illumina and Loxo Oncology have announced a global strategic partnership to develop a diagnostic tool that will work with Loxo’s larotrectinib and another of its experimental cancers drugs, across tumour types.